N-iso-propyl-2,4-dimethoxybenzylamine | 940356-64-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-iso-propyl-2,4-dimethoxybenzylamine
• 英文别名: [(2,4-Dimethoxyphenyl)methyl](propan-2-yl)amine；N-[(2,4-dimethoxyphenyl)methyl]propan-2-amine
• CAS: 940356-64-9
• 化学式: C₁₂H₁₉NO₂
• mdl: MFCD08757576
• 分子量: 209.288
• InChiKey: RQFBSHALMPPOJT-UHFFFAOYSA-N

物化性质

• 沸点：
  290.9±25.0 °C(Predicted)
• 密度：
  0.985±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  30.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  乙酰氧基乙酸 、 N-iso-propyl-2,4-dimethoxybenzylamine 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 17.0h， 生成
  参考文献：
  名称：

  A Dearomatizing, Thionium Ion Cyclization for the Synthesis of Functionalized, Azaspirocyclic Cyclohexadienones

  摘要：

  Thionium ions, generated by the addition of thiols to N-benzylglyoxamides, undergo a dearomatizing spirocyclization. The alkyl or arylsultanyl group introduced during the thionium ion cyclization can act as a synthetic handle and a stereochemical control element during modifications of the azaspirocyclic frameworks (R(F) = CH(2)CH(2)C(8)F(17)).

  DOI：

  10.1021/ol8002095

文献信息

• [EN] FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES<br/>[FR] DÉRIVÉS DE PYRIMIDONE À CYCLES FUSIONNÉS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT D'UNE INFECTION PAR LE VIRUS DE L'HÉPATITE B OU DE MALADIES INDUITES PAR LE VIRUS DE L'HÉPATITE B
  申请人：JANSSEN SCIENCES IRELAND UNLIMITED CO

  公开号：WO2020182990A1

  公开（公告）日：2020-09-17

  The present application relates to compounds according to Formula (I), pharmaceutical compositions comprising at least one of said compounds, their use as a medicament, and their use in treating chronic hepatitis B virus (HBV) infection. The disclosure further pertains to methods for preparing compounds according to Formula (I).

  本申请涉及按照式(I)的化合物，包括至少一种所述化合物的药物组合物，其作为药物的用途，以及其在治疗慢性乙型肝炎病毒（HBV）感染中的用途。该公开还涉及按照式(I)制备化合物的方法。
• Modulators of ROR-gamma Receptors, Composition and Use Thereof
  申请人：KULING THERAPEUTICS

  公开号：US20170298090A1

  公开（公告）日：2017-10-19

  The present invention provides novel methods to treat disease by modulating retinoid-related orphan receptor gamma (ROR-gamma) in vitro and in vivo with ursolic acid analogs, and compositions thereof. The methods and compounds disclosed herein are useful for inhibiting the differentiation of a population of T cells, or treating a disease related to Th17 cell responses in a subject. Examples of such diseases include, but are not limited to, autoimmune diseases, multiple sclerosis, rheumatoid arthritis, psoriasis and diabetes.

  本发明提供了一种通过使用熊果酸类似物在体外和体内调节视黄醇相关孤儿受体γ（ROR-gamma）来治疗疾病的新方法，以及相关组合物。本文披露的方法和化合物对于抑制T细胞群体的分化或治疗与Th17细胞反应相关的疾病非常有用。此类疾病的示例包括但不限于自身免疫疾病、多发性硬化症、类风湿性关节炎、牛皮癣和糖尿病。
• HYDROXYTHIENOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS
  申请人：BRADBURY Barton James

  公开号：US20100256112A1

  公开（公告）日：2010-10-07

  Disclosed herein are hydroxylthienoquinolones and related compounds and their pharmaceutically acceptable salts useful as antiviral agents and having the general formula in which the variables R 2 , R 6 , and R 7 are defined herein. Certain compounds provided herein possess potent antibacterial, antiprotozoal, or antifungal activity and are particularly efficacious for the treatment of MRSA infections. The invention also provides pharmaceutical compositions, pharmaceutical compositions containing a hydroxylthienoquinolone in combination with one or more other active agent, and methods of treating microbial infections in animals by administering an effective amount of a hydroxylthienoquinolone or related compound to an animal suffering from a microbial infection.

  本文披露了羟基噻唑喹啉和相关化合物及其药学上可接受的盐，可用作抗病毒剂，并具有以下通用式的R2、R6和R7变量的定义。本文提供的某些化合物具有强大的抗菌、抗原虫或抗真菌活性，并特别适用于治疗MRSA感染。本发明还提供了制药组合物、含有羟基噻唑喹啉与一种或多种其他活性剂的制药组合物，以及通过向患有微生物感染的动物投予有效量的羟基噻唑喹啉或相关化合物来治疗动物的微生物感染的方法。
• Kinase inhibitors
  申请人：Spada Lon T.

  公开号：US20090286773A1

  公开（公告）日：2009-11-19

  The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.

  本发明涉及药物输送系统，包括眼部植入物，其中包括有机分子，能够调节酪氨酸激酶信号转导，以调节、调节和/或抑制异常细胞增殖，与聚合物结合，该聚合物用于控制、修改、调节和/或减缓治疗成分进入放置该复合物的眼部环境中的释放。
• Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10568876B2

  公开（公告）日：2020-02-25

  The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula (I) are inhibitors of diacylglyceride O-acyltransferase 2 (“DGAT2”) and may be useful in the treatment, prevention and suppression of diseases mediated by DGAT2. The compounds of the present invention may be useful in the treatment of hepatic steatosis, diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions.

  本发明涉及由式（I）代表的化合物及其药学上可接受的盐类。式（I）化合物是二酰基甘油 O-酰基转移酶 2（"DGAT2"）的抑制剂，可用于治疗、预防和抑制由 DGAT2 介导的疾病。本发明的化合物可用于治疗肝脂肪变性、糖尿病、肥胖症、高脂血症、高胆固醇血症、动脉粥样硬化、心肾疾病（如慢性肾脏疾病和心力衰竭）以及相关疾病和病症。